Blog
RSS FeedPosted by Michael Wonder on 04 Dec 2018
Flexibility on cancer drugs approval will foster innovation
4 December 2018 - Between 2000 and 2016, no new drugs were approved for cancers of the brain, and there were ...
Posted by Michael Wonder on 04 Dec 2018
New cancer drugs taking longer to reach NHS patients
4 December 2018 - NHS patients are waiting longer for new cancer drugs because of delays in taking them through ...
Posted by Michael Wonder on 28 Nov 2018
First children set to receive Novartis’ Kymriah
27 November 2018 - The first children to receive Novartis’ Kymriah – a ‘game-changing’ CAR-T therapy for cancer - will ...
Posted by Michael Wonder on 26 Nov 2018
UK pharma industry reacts to outcome of European Council meeting
25 November 2018 - The European Council has endorsed the Agreement on the withdrawal of the UK from the EU and ...
Posted by Michael Wonder on 23 Nov 2018
Faster access to groundbreaking medicines as major milestones reached in deal with pharmaceutical industry
23 November 2018 - Cutting-edge and best value drugs will be fast-tracked through the approval process so patients can gain access ...
Posted by Michael Wonder on 23 Nov 2018
Lords ask Minister for clarity on access to medicine after Brexit
23 November 2018 - The House of Lords EU Home Affairs Sub-Committee has written to Matt Hancock MP, Secretary of ...
Posted by Michael Wonder on 19 Nov 2018
Pharma ignores the squabbling and prepares for a hard Brexit
19 November 2018 - Costs are irrecoverable in industry that has to plan for all possible scenarios. ...
Posted by Michael Wonder on 19 Nov 2018
Innovative skin cancer drug available on Cancer Drugs Fund
19 November 2018 - Patients with a type of advanced skin cancer have a new treatment option as pembrolizumab, also known ...
Posted by Michael Wonder on 17 Nov 2018
BHA, ABPI welcome UK’s EU withdrawal agreement
16 November 2018 - The Brexit Health Alliance has welcomed the agreement on the terms of the UK’s withdrawal from ...
Posted by Michael Wonder on 12 Nov 2018
Availability of Orkambi on the NHS
9 November 2018 - The Health and Social Care Committee has formally requested documents from Vertex Pharmaceuticals, NHS England and ...
Posted by Michael Wonder on 24 Oct 2018
MS and cholesterol drugs picked for new UK rapid uptake push
24 October 2018 - Accelerated Access Collaborative aims to break down barriers to faster uptake ...
Posted by Michael Wonder on 20 Oct 2018
Some European countries decide to cover cancer drugs much faster than others
19 October 2018 - Some European countries take more than twice as long as others to decide whether to provide ...
Posted by Michael Wonder on 05 Oct 2018
Gilead strikes deal with NHS England on CAR-T Yescarta
5 October 2018 - NHS England claims adult leukaemia access is first in Europe. ...
Posted by Michael Wonder on 02 Oct 2018
Denmark funds Vertex’s cystic fibrosis drug Orkambi, UK talks deadlocked
2 October 2018 - As uncertainty hangs over the availability of Vertex’s cystic fibrosis drug in England, the company has ...
Posted by Michael Wonder on 01 Oct 2018
NHS England agrees to fund Janssen’s Symtuza
1 October 2018 - NHS England has agreed to provide funding for Janssen’s Symtuza, a once-daily darunavir-based single tablet regimen ...